News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales.
News Taking lenient stance, NICE backs neuroblastoma drug Body makes special case due to rarity of the disease
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
